FDA grants priority review to AZN's filing for rare bone disease drug. Priority review accelerates potential approval and adds to AZN pipeline for future revenue.
| Nov 25 | Feb 26 | May 26 | Aug 26 | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Buy | — | — | — | — | — | — | — | — | — | — | 1 | — |
| Sell | — | — | — | — | — | — | — | 1 | — | — | — | — |
| total | individual payouts | |
|---|---|---|
| 2028 | ‡‡‡‡‡ |
|
| 2027 | ‡‡‡‡‡ |
|
| 2026 | 3.21 |
—
—
|
| 2025 | 3.13 |
—
—
|
| 2024 | 2.97 |
—
—
|
| 2023 | 2.90 |
—
—
|
| 2022 | 2.90 |
—
—
|
| 2021 | 2.80 |
—
—
|
| 2020 | 2.80 |
—
—
|
| 2019 | 2.80 |
—
—
|
| 2018 | 2.80 |
—
—
|
| 2017 | 2.80 |
—
—
|
| 2016 | 2.80 |
—
—
|
| 2023 | 2024 | 2025 | Q'26 | |
|---|---|---|---|---|
| Cash | 6,078.00 | 5,708.00 | 5,831.00 | 5,044.00 |
| Receivables | 13,552.00 | 14,831.00 | 16,335.00 | 15,989.00 |
| Inventory | 5,424.00 | 5,288.00 | 6,557.00 | 6,932.00 |
| Other | — | — | — | — |
| 25,054.00 | 25,827.00 | 28,723.00 | 27,965.00 |
| 2023 | 2024 | 2025 | Q'26 | |
|---|---|---|---|---|
| Payables | 22,374.00 | 22,465.00 | 25,280.00 | 22,893.00 |
| ST’ Debt | 5,129.00 | 2,337.00 | 3,104.00 | 5,808.00 |
| Other | 1,184.00 | 1,319.00 | 767.00 | 958.00 |
| 30,542.00 | 27,866.00 | 30,617.00 | 31,553.00 |
| 10y | 5y | 3y | |
| Sales | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ |
| Cash Flow | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ |
| Earnings | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ |
| Book Value | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ |
| Mar | Jun | Sep | Dec | Year | |
|---|---|---|---|---|---|
| ’26 | 15,288.00 | 15,384.00 | — | — |
—
|
| ’25 | 13,588.00 | 14,457.00 | 15,191.00 | 15,503.00 |
58,739.00
|
| ’24 | 12,679.00 | 12,938.00 | 13,565.00 | 14,891.00 |
54,073.00
|
| ’23 | 10,879.00 | 11,416.00 | 11,492.00 | 12,024.00 |
45,811.00
|
| ’22 | 11,390.00 | 10,771.00 | 10,982.00 | 11,208.00 |
44,351.00
|
| ’21 | 7,320.00 | 8,220.00 | 9,866.00 | 12,011.00 |
37,417.00
|
| ’20 | 6,354.00 | 6,275.00 | 6,578.00 | 7,410.00 |
26,617.00
|
| Mar | Jun | Sep | Dec | Year | |
|---|---|---|---|---|---|
| ’26 | 3,359.00 | 2,865.00 | — | — |
—
|
| ’25 | 3,713.00 | 3,386.00 | 5,134.00 | 2,342.00 |
14,575.00
|
| ’24 | 2,486.00 | 3,085.00 | 3,383.00 | 2,907.00 |
11,861.00
|
| ’23 | 3,133.00 | 1,718.00 | 3,114.00 | 2,380.00 |
10,345.00
|
| ’22 | 3,232.00 | 1,248.00 | 2,930.00 | 2,398.00 |
9,808.00
|
| ’21 | 1,934.00 | 892.00 | 1,719.00 | 1,418.00 |
5,963.00
|
| ’20 | 139.00 | 1,040.00 | 1,822.00 | 1,798.00 |
4,799.00
|
| Mar | Jun | Sep | Dec | Year | |
|---|---|---|---|---|---|
| ’26 | 1,874.00 | (116.00) | — | — |
—
|
| ’25 | 2,754.00 | 1,558.00 | 3,409.00 | 1,098.00 |
8,819.00
|
| ’24 | 1,009.00 | 2,417.00 | 2,057.00 | 1,970.00 |
7,453.00
|
| ’23 | 2,052.00 | 1,260.00 | 2,240.00 | 1,438.00 |
6,990.00
|
| ’22 | 3,254.00 | 762.00 | 1,836.00 | 2,114.00 |
7,966.00
|
| ’21 | 1,887.00 | 694.00 | 1,076.00 | 706.00 |
4,363.00
|
| ’20 | 128.00 | 239.00 | 1,307.00 | 1,576.00 |
3,250.00
|
| Mar | Jun | Sep | Dec | Year | |
|---|---|---|---|---|---|
| ’26 | 1.97 | 1.61 | — | — |
—
|
| ’25 | 1.86 | 1.58 | 1.62 | 1.49 |
6.54
|
| ’24 | 1.40 | 1.24 | 0.92 | 0.96 |
4.50
|
| ’23 | 1.16 | 1.18 | 0.88 | 0.62 |
3.82
|
| ’22 | 0.26 | 0.24 | 1.06 | 0.58 |
2.12
|
| ’21 | 1.18 | 0.42 | (1.10) | (0.22) |
0.08
|
| ’20 | 0.60 | 0.58 | 0.50 | 0.78 |
2.44
|
| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡ | ‡‡‡‡ | ‡‡‡‡‡ | 105.30 | 123.46 | 120.94 | 122.48 | — | — | — |
Low Price
|
| ‡‡‡‡‡ | ‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | 143.40 | 153.12 | 175.36 | 188.04 | — | — | — |
High Price
|
| ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | 83,500 | 89,900 | 94,300 | 96,100 | — | — | — |
Employees
|
| ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | 0.53 | 0.51 | 0.57 | 0.61 | — | — | — |
Revenue/Emp
|
| ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | 44,351.00 | 45,811.00 | 54,073.00 | 58,739.00 | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ |
Revenue
|
| ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | 72.06% | 81.95% | 81.12% | 81.90% | — | — | — |
Gross Margin
|
| ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | 2,501.00 | 6,899.00 | 8,691.00 | 12,402.00 | — | — | — |
EBT
|
| ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | 5.64% | 15.06% | 16.07% | 21.11% | ‡‡‡ | ‡‡‡ | ‡‡‡ |
EBT Margin
|
| ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | 2,501.00 | 6,899.00 | 8,691.00 | 12,402.00 | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ |
Net Income
|
| ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | 5,480.00 | 5,387.00 | 6,688.00 | 5,733.00 | — | — | — |
Depreciation
|
| ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | 28.65 | 29.57 | 17.44 | 18.95 | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ |
Revenue/Sh
|
| ‡‡‡‡ | ‡‡‡‡ | ‡‡‡ | ‡‡‡‡ | ‡‡‡‡ | ‡‡‡‡ | 2.12 | 3.84 | 4.54 | 6.60 | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ |
Earnings/Sh
|
| ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | 6.34 | 6.68 | 3.83 | 4.70 | — | — | — |
Cash Flow/Sh
|
| ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | (1.19) | (2.17) | (1.42) | (1.86) | ‡‡‡ | ‡‡‡ | ‡‡‡ |
Capex/Sh
|
| ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | 5.15 | 4.51 | 2.40 | 2.84 | — | — | — |
Free CF/Sh
|
| ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | 23.94 | 25.28 | 13.18 | 15.72 | — | — | — |
Book Value/Sh
|
| ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | 1,548.00 | 1,549.00 | 3,100.00 | 3,100.00 | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ |
Shares
|
| ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | 64.79 | 35.44 | 28.74 | 27.86 | ‡‡‡‡ | ‡‡‡‡ | ‡‡‡‡ |
PE Ratio
|
| ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | 4.84 | 4.63 | 7.51 | 9.70 | ‡‡‡ | ‡‡‡ | ‡‡‡ |
PS Ratio
|
| ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | 5.79 | 5.41 | 9.94 | 11.70 | ‡‡‡ | ‡‡‡ | ‡‡‡ |
PB Ratio
|
| ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | 5.33 | 5.09 | 7.94 | 10.08 | ‡‡‡‡ | ‡‡‡‡ | ‡‡‡‡ |
EV/Sales
|
| ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | 29.68 | 33.38 | 57.61 | 67.12 | — | — | — |
EV/FCF
|
| ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | 9,808.00 | 10,345.00 | 11,861.00 | 14,575.00 | ‡‡‡ | ‡‡‡ | ‡‡‡ |
Op' Cash Flow
|
| ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | (1,842.00) | (3,355.00) | (4,408.00) | (5,756.00) | ‡‡‡‡‡ | ‡‡‡‡‡ | — |
Capex
|
| ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | 7,966.00 | 6,990.00 | 7,453.00 | 8,819.00 | — | — | — |
FCF
|
| ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | (3,700.00) | (5,488.00) | (2,039.00) | (1,894.00) | — | — | — |
Working Cap'
|
| ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | 28,279.00 | 27,494.00 | 28,843.00 | 27,819.00 | — | — | — |
Total Debt
|
| ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | 21,787.00 | 21,416.00 | 23,135.00 | 21,988.00 | — | — | — |
Net Debt
|
| ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | 37,058.00 | 39,166.00 | 40,871.00 | 48,719.00 | — | — | — |
Sh' Equity
|
| ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | 3.26% | 6.03% | 6.86% | 9.38% | — | — | — |
ROA
|
| ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | 3.99% | 8.45% | 9.77% | 12.15% | — | — | — |
ROIC
|
| ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | 8.61% | 15.63% | 17.58% | 22.83% | — | — | — |
ROE
|
AstraZeneca PLC (AZN) exemplifies resilience in biopharma, evolving from its 2016 lows to a projected $190 stock high by 2025, fueled by revenue doubling from $26.6 billion in 2020 to a forecasted $66.3 billion in 2027. Post-COVID vaccine surge, diversification via oncology blockbusters like Tagrisso, Enhertu, and Imfinzi, plus the $39 billion Alexion acquisition, has driven consistent growth—18% in 2024 alone—while revenue per employee hit $573,000, underscoring operational efficiency amid headcount expansion.
Profitability has rebounded sharply, with EBT swinging from a 2021 loss to $12.4 billion projected for 2025 (21.1% margins) and ROE climbing to 22.8%, supported by 80%+ gross margins and $7.5 billion FCF in 2024. Trading at a forward P/E of 26-28x—attractive for high-teens growth—AZN offers undervalued entry amid analyst targets implying up to 36% upside, backed by pipeline catalysts in ADCs and rare diseases.
Balanced risks like patent cliffs and capex intensity are mitigated by a fortified balance sheet and macro tailwinds, positioning AZN for multi-year outperformance in disruptive therapies.
Keep track of companies that you follow and research.
Full access to our data with predictions and indicators that we calculate daily.
Full access to our screener with tons of custom values and customizable email notifications.
Excel export of financials and screeners you define and save.